- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07896486
Evaluating a Brightening Serum for Post-Inflammatory Hyperpigmentation
A Single-Center, Open-Label Study to Assess the Efficacy and Tolerability of a Brightening Serum in Skin of Color Patients With Post Inflammatory Hyperpigmentation
This study is designed to evaluate the effectiveness and safety of Vinoperfect, a skin-brightening serum, for treating post-inflammatory hyperpigmentation (PIH), or dark spots that can develop after acne, in participants with Fitzpatrick Skin Types IV-VI (medium to deep skin tones). The study will assess Vinoperfect as part of a comprehensive skincare routine that includes cleansing, treatment, moisturization, and protection from sunlight.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
This is a single-center, open-label trial designed to assess the efficacy and tolerability of a skin brightening serum in individuals with skin of color who are diagnosed with acne-induced Post-Inflammatory Hyperpigmentation on the facial skin. The study will be conducted at a single site, enrolling male and female participants from a range of ethnic/racial backgrounds, all with Fitzpatrick Skin Types IV-VI. Study participation will last for 12 weeks.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Andrew Alexis, MD, MPH
- Telefonnummer: 6469623376
- E-post: dermres@med.cornell.edu
Studera Kontakt Backup
- Namn: Angelica Nazarian, MD
- Telefonnummer: 6469622090
- E-post: dermres@med.cornell.edu
Studieorter
-
-
New York
-
New York, New York, Förenta staterna, 10022
- Rekrytering
- Weill Cornell Medicine Dermatology
-
Kontakt:
- Angelica Nazarian, MD
- Telefonnummer: 6469622090
- E-post: dermres@med.cornell.edu
-
Kontakt:
- Olumayowa Adebiyi, MD, MHS
- Telefonnummer: 6469626054
- E-post: dermres@med.cornell.edu
-
Huvudutredare:
- Andrew Alexis, MD, MPH
-
Underutredare:
- Angelica Nazarian, MD
-
Underutredare:
- Olumayowa Adebiyi, MD, MHS
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Male or female participants aged ≥18 years.
- Participants with Fitzpatrick Skin Types IV, V, or VI.
- Participants of any ethnicity.
- Presenting with moderate to severe post-inflammatory hyperpigmentation, as determined by a PAHPI score of 8 or higher.
- Presenting with history or presence of mild acne, as indicated by a Global Acne Severity Score of 2 or lower (GEA ≤ 2).
- Capable of understanding and communicating in English, and willing to provide written informed consent to participate in the study.
- Willing to comply with study requirements, including attending all scheduled in-person follow-up visits as outlined in the protocol.
- Willing to undergo facial photography.
- Willing to undergo facial examination for clinical evaluation.
- In good general health, free of any other dermatologic conditions that may interfere with the assessment of the treated area.
- Willing to refrain from using any other facial skincare products during the study period.
- Willing to avoid excessive sun exposure and tanning beds during the study period.
- Willing to refrain from undergoing chemical peels, laser rejuvenation, or hair removal treatments during the study period.
- For females of childbearing potential: willing to use at least one reliable form of contraception, defined as stable use of oral or systemic contraceptives for at least 6 months prior to Day 1 of the study and throughout the study duration.
Exclusion Criteria:
- Participants with Fitzpatrick Skin Types I, II, or III.
- Pregnant or breastfeeding participants.
- Individuals presenting with moderate to very severe acne, as indicated by a Global Acne Severity Score of 3 or higher (GEA > 3).
- Participants with known allergies or sensitivities to any active or inactive ingredients in the study products.
- Participants with dermatologic conditions that may interfere with the evaluation of the treatment area.
- Individuals with regular sun exposure or frequent use of tanning salons.
- Participants currently enrolled in another clinical study.
- Participants who have used the following treatments or procedures within a specific washout periods (to be discussed with the study investigators).
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Övrig: Participants with Acne-Associated Post-Inflammatory Hyperpigmentation using the Vinoperfect Serum
Participants will undergo a standardized twice-daily skincare regimen for 12 weeks. In the morning, participants will cleanse their face, apply the Vinoperfect Brightening Serum, apply moisturizer, and then apply SPF 50+ sunscreen. In the evening, participants will cleanse their face, apply the Vinoperfect Brightening Serum, and apply moisturizer. |
Participants will undergo a standardized twice-daily skincare regimen for 12 weeks. In the morning, participants will cleanse their face, apply the Vinoperfect Brightening Serum, apply moisturizer, and then apply SPF 50+ sunscreen. In the evening, participants will cleanse their face, apply the Vinoperfect Brightening Serum, and apply moisturizer. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from baseline in PIH of the face at Week 12, as assessed by the Post-Acne Hyperpigmentation Index (PAHPI) score
Tidsram: Baseline; 12 weeks
|
Total scores on the PAHPI range from 6 to 22, with higher scores indicating greater severity of post-acne hyperpigmentation |
Baseline; 12 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number or participants who tolerated the investigational product as assessed by the investigator
Tidsram: Up to 12 weeks
|
Investigator-assessed tolerability of the investigational product based on the presence and severity of local or systemic adverse reactions potentially attributable to the investigational product. |
Up to 12 weeks
|
|
Patient-reported stigmatization, as measured by the PUSH-D questionnaire at week 12
Tidsram: Baseline; Week 12
|
Change from baseline in Patient-Reported Stigmatization, as measured by the PUSH-D (Patient Use and Satisfaction with Hyperpigmentation Dermocosmetic) questionnaire at Week 12. The PUSH-D is a 17-item patient-reported questionnaire assessing felt and enacted stigma associated with visible skin conditions. Total score range from 0 to 68 with higher scores indicating more felt/perceived stigma. |
Baseline; Week 12
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Andrew Alexis, MD, MPH, Weill Medical College of Cornell University
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 26-01029789
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .